Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Canadian patients have less access to the latest medicines, says report

Canadian patients have less access to the latest medicines when compared to the world's developed countries, concludes a comprehensive new report released today. The Report shows Canada ranks 20th out of 25 OECD countries in public reimbursement of new drug therapies. Canada's grade of 56% is comparable with Iceland, Slovakia and Turkey.

4 Nov 2009

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Pfizer Inc and Medivation, Inc. today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD).

4 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

New study to assess preventative brain radiation therapy for lung cancer patients

A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain.

3 Nov 2009

High blood pressure and an innate pro-inflammatory cytokine response contribute to Alzheimer's disease

High blood pressure, evidence of arterial disease and markers of inflammation in the blood in middle age appear more common in individuals whose parents have Alzheimer's disease than in individuals without a parental history of the condition, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Nov 2009

Brain disorder that causes early dementia is highly hereditary: Study

New research shows that a rare brain disorder that causes early dementia is highly hereditary. The study is published in the November 3, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

3 Nov 2009

ExonHit Therapeutics to take part in MAPT study for early detection of Alzheimer’s disease

ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l’Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study’s main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.

2 Nov 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

Geron plans to advance clinical program for spinal cord injury

Geron Corporation today announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.

31 Oct 2009

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN).

30 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition

Isotechnika Pharma Inc. today announced that it has developed a portfolio of non-immunosuppressive cyclosporine analogue molecules (NICAMs) with potent cyclophilin inhibition. Cyclophilin inhibition has garnered considerable attention as a novel therapy in the treatment of a wide range of diseases including hepatitis C, stroke, and chronic neurological disorders such as Parkinson's, Lou Gehrig's, and Alzheimer's.

30 Oct 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009

New study reviews science behind the efficacy of biofield therapies on pain management

Biofield therapies, which claim to use subtle energy to stimulate the body's healing process, are promising complementary interventions for reducing the intensity of pain in a number of conditions, reducing anxiety for hospitalized patients and reducing agitated behaviors in dementia, over and above what standard treatments can achieve.

30 Oct 2009

Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure

Case Western Reserve University School of Medicine has received a $14.7 million, nine-year contract from the National Institutes of Health to be one of five institutions to lead a trial to determine if lowering systolic blood pressure in hypertensive patients, without diabetes, to below the currently recommended level can reduce the incidence of cardiovascular and kidney disease and slow cognitive decline.

30 Oct 2009

Dr. Heather Greene to receive 2009 C.A.R.E. Pharmacy Award

Eisai Inc. and the Alzheimer's Association announce today that Heather Greene, PharmD is the recipient of the 2009 C.A.R.E. Pharmacy Award.

30 Oct 2009

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

The National Institutes of Health is launching a large multicenter randomized clinical trial to determine whether maintaining blood pressure levels lower than current recommendations further reduces the risk of cardiovascular and kidney diseases, or age-related cognitive decline.

30 Oct 2009

New reports detail hits taken by Medicaid programs in state budget cuts

State Medicaid and other health programs have fallen under the axe or been moved onto the chopping block this week.

29 Oct 2009

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Canadian patients have less access to the latest medicines, says report

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Arrowhead Research updates its shareholders

New study to assess preventative brain radiation therapy for lung cancer patients

High blood pressure and an innate pro-inflammatory cytokine response contribute to Alzheimer's disease

Brain disorder that causes early dementia is highly hereditary: Study

ExonHit Therapeutics to take part in MAPT study for early detection of Alzheimer’s disease

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Geron plans to advance clinical program for spinal cord injury

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Eisai reports global Phase III study results of eribulin mesylate

Isotechnika Pharma develops portfolio of NICAMs with potent cyclophilin inhibition

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

New state-of-the-art biotechnology center opened on the West Coast

New study reviews science behind the efficacy of biofield therapies on pain management

Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure

Dr. Heather Greene to receive 2009 C.A.R.E. Pharmacy Award

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

New reports detail hits taken by Medicaid programs in state budget cuts

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in